Letter by Mascitelli and Goldstein Regarding Article, “Is Statin Monotherapy the Perfect Polypill?”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Ridker1 compared, in a primary prevention setting, the relative risk reductions observed in both the rovustatatin 10 mg daily arm and the rosuvastatin (10 mg per day) plus candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg per day) arm of the HOPE-3 trial2 (Heart Outcomes Prevention Evaluation-3), with the relative risk reductions observed in …